Dental Care Clinics in Spring Lake, NC Accepting Medicare
7 Dental Care Clinics found. Showing 1 - 7
 Spring Lake Dental Group Clinic/Center - Dental Medicare: Not Enrolled in Medicare Practice Location: 103 Superior Drive, Spring Lake, NC 28390 Phone: 910-497-3200 Fax: 910-497-2209 |
Carolinas Dentist Oral Surgery Dentist - Oral and Maxillofacial Surgery Medicare: Not Enrolled in Medicare Practice Location: 620 Lillington Hwy, Spring Lake, NC 28390 Phone: 330-951-9153 |
Firehouse Kid's Dentistry Dentist - Pediatric Dentistry Medicare: Not Enrolled in Medicare Practice Location: 2980 Ray Road, Spring Lake, NC 28390 Phone: 910-778-8485 Fax: 910-778-8477 |
Spring Lake Dental Center Dentist - General Practice Medicare: Not Enrolled in Medicare Practice Location: 203 S Main St, Spring Lake, NC 28390 Phone: 910-497-2969 Fax: 910-497-6505 |
Dentistry Of The Carolinas Dentist - General Practice Medicare: Not Enrolled in Medicare Practice Location: 101 Sleepy Dr, Suite 102, Spring Lake, NC 28390 Phone: 910-497-2969 Fax: 910-497-6505 |
Carolinasdentist.com Clinic/Center - Dental Medicare: Not Enrolled in Medicare Practice Location: 620 Lillington Hwy, Spring Lake, NC 28390 Phone: 919-225-0613 |
Anderson Creek Dental Clinic Dentist Medicare: Not Enrolled in Medicare Practice Location: 6720 Overhills Rd, Spring Lake, NC 28390 Phone: 910-436-3194 Fax: 910-436-3195 |
News Archive
DMC concludes Protege Phase 3 clinical trial for type 1 diabetes lacks efficacy
MacroGenics, Inc. and Eli Lilly and Company today announced that the Protege Data Monitoring Committee (DMC), composed of independent experts in the fields of diabetes and biostatistics, has completed a planned analysis of one-year safety and efficacy data of the Protege Phase 3 clinical trial of teplizumab, an investigational biologic under development for the treatment of individuals with recent-onset type 1 diabetes.
Positive results from Shire's velaglucerase alfa Phase III study for Type 1 Gaucher disease
Shire plc, the global specialty biopharmaceutical company, today presented positive results from its first Phase III study (TKT 032) evaluating safety and efficacy of velaglucerase alfa, its investigational enzyme replacement therapy for the treatment of Type 1 Gaucher disease. The data were presented in an oral presentation at the Lysosomal Disease Network (LDN) World Symposium in Miami, Florida.
Exploring how absence of ASS1 protein affects sick children may provide a 'lens' on cancer
What can a rare genetic childhood disease teach us about cancer? Dr. Ayelet Erez of the Weizmann Institute of Science's Department of Biological Regulation says: "A single-mutation disease can act as a 'lens.' If we find exactly what malfunctions in the sick child, we can zoom in and understand the role of the same gene among the many genetic changes that accompany cancer."
Total COVID-19 deaths could be 7 million
A new analysis from the Institute for Health Metrics and Evaluation (IHME), which independently researches health at the University of Washington School of Medicine, shows that the total global toll due to coronavirus disease 2019 (COVID-19) could be more than twice the officially reported number of deaths, at almost 7 million.
New report measures growing adoption of centralized ECG services
ERT, a global provider of technology and services to the pharmaceutical, biotechnology and medical device industries, announced today the availability of a new report, conducted by the Tufts Center for the Study of Drug Development, mapping the growing adoption of centralized ECG (electrocardiogram) services. The industry-wide report measures the current and anticipated adoption levels of centralized ECGs in clinical trials.
› Verified 9 days ago